FDA Approves Opdivo Plus Chemotherapy for Gastric Cancer
The FDA has approved Opdivo in combination with chemotherapy for the treatment of gastric cancer, marking a significant advancement in cancer care.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 02, 2026
The U.S. Food and Drug Administration (FDA) has granted approval for nivolumab (Opdivo) in combination with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma. This FDA Opdivo approval signifies a notable advancement in the treatment of this aggressive cancer, offering improved survival outcomes compared to chemotherapy alone and reflects the growing importance of immuno-oncology in cancer care.
Drug Overview
Nivolumab (Opdivo) is a fully human IgG4 monoclonal antibody and a PD-1 immune checkpoint inhibitor. It works by blocking the interaction between PD-1 receptors on T cells and its ligands PD-L1 and PD-L2, thereby enhancing the anti-tumor immune response. It is approved for use in combination with chemotherapy as a first-line treatment for adults with unresectable locally advanced, recurrent, or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma.
Clinical Insights
The nivolumab approval is supported by clinical trials demonstrating improved overall survival and progression-free survival compared to chemotherapy alone. The trials enrolled patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Key efficacy endpoints included overall survival (OS) and progression-free survival (PFS), both showing statistically significant improvement with the combination therapy. The safety profile was consistent with known adverse events of nivolumab and chemotherapy, with manageable side effects.
Regulatory Context
The nivolumab approval followed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The approval was based on Phase 3 randomized controlled trials demonstrating clinical benefit. Post-marketing commitments and pharmacovigilance are standard.
Market Impact
The introduction of nivolumab plus chemotherapy offers a novel first-line treatment option, potentially increasing market share in immuno-oncology and expanding therapeutic choices for gastric cancer. The gastric cancer market includes chemotherapy agents and targeted therapies like trastuzumab. Nivolumab expands options for HER2-negative or unselected patients, and provides improved survival benefits over chemotherapy alone, representing a significant advancement over existing chemotherapy and targeted therapy options.
Future Outlook
Ongoing studies may explore further combinations and indications in gastric and gastroesophageal cancers. The nivolumab approval may shift treatment paradigms by integrating immunotherapy with chemotherapy in earlier lines of therapy.
Frequently Asked Questions
What is the new indication for nivolumab (Opdivo)?
Nivolumab (Opdivo) is now approved in combination with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma.
How does nivolumab work?
Nivolumab is a PD-1 immune checkpoint inhibitor that enhances anti-tumor immune response by blocking the PD-1 receptor on T cells.
What were the key findings from the clinical trials supporting this approval?
Clinical trials demonstrated improved overall survival and progression-free survival compared to chemotherapy alone.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-02.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
